Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Therapeutic Drug Monitoring: Overview and Classification01:16

Therapeutic Drug Monitoring: Overview and Classification

139
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
139
Drug Therapy01:28

Drug Therapy

179
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
179
Preclinical Development: Overview01:28

Preclinical Development: Overview

5.6K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.6K
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

724
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
724
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence01:22

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

104
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
104
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

1.0K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Thrombin Generation Induced by Complement Component C1q Interaction With the Receptor for the Globular Head of C1q on Adventitial Fibroblasts and Vascular Smooth Muscle Cells.

Immunity, inflammation and disease·2026
Same author

Can Novel Biomarkers Augment Traditional Surveillance Paradigms in Early-stage Testicular Germ Cell Tumors? A Case Study in Pre-clinical Relapse Detection Using a Combination Micro-RNA-371a-3p and 372-3p Assay.

Urology·2025
Same author

A High-Fiber, Plant-Based Diet in Myeloma Precursor Disorders: Results from the NUTRIVENTION Clinical Trial and Preclinical Vk*MYC Model.

Cancer discovery·2025
Same author

Comparison of serum and plasma microRNA expression levels in patients with germ cell tumours.

BJU international·2025
Same author

Alzheimer's Disease: In Vitro and In Vivo Evidence of Activation of the Plasma Bradykinin-Forming Cascade and Implications for Therapy.

Cells·2025
Same author

Omics analysis reveals galectin-3 to be a potential key regulator of allergic inflammation in hereditary angioedema.

The journal of allergy and clinical immunology. Global·2024

Related Experiment Video

Updated: Dec 3, 2025

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices
06:34

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Published on: November 29, 2024

476

SLE: Novel Postulates for Therapeutic Options.

Kinga K Hosszu1, Alisa Valentino2, Ellinor I Peerschke2

  • 1Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, United States.

Frontiers in Immunology
|October 29, 2020
PubMed
Summary

Genetic deficiency in C1q is linked to systemic lupus erythematosus (SLE). C1q regulates monocyte to dendritic cell (DC) differentiation, and its absence may impair self-tolerance, suggesting C1q/C1qR as a therapeutic target for SLE.

Keywords:
SLEc1qcC1qRcomplementgC1qRnovel hypothesis

More Related Videos

Method for Novel Anti-Cancer Drug Development using Tumor Explants of Surgical Specimens
09:26

Method for Novel Anti-Cancer Drug Development using Tumor Explants of Surgical Specimens

Published on: July 29, 2011

16.9K
Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B
11:44

Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B

Published on: January 19, 2022

2.8K

Related Experiment Videos

Last Updated: Dec 3, 2025

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices
06:34

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Published on: November 29, 2024

476
Method for Novel Anti-Cancer Drug Development using Tumor Explants of Surgical Specimens
09:26

Method for Novel Anti-Cancer Drug Development using Tumor Explants of Surgical Specimens

Published on: July 29, 2011

16.9K
Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B
11:44

Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B

Published on: January 19, 2022

2.8K

Area of Science:

  • Immunology
  • Molecular Biology
  • Rheumatology

Background:

  • Genetic deficiency in C1q is a significant risk factor for developing systemic lupus erythematosus (SLE).
  • Two main hypotheses explain C1q's role in SLE: impaired apoptotic cell clearance and dysregulated monocyte-to-dendritic cell (DC) differentiation.
  • C1q plays a crucial role in maintaining immune homeostasis by regulating early monocyte differentiation and function.

Purpose of the Study:

  • To review the role of C1q and its receptors (C1qRs) in the pathogenesis of SLE.
  • To explore the C1q/gC1qR axis as a potential therapeutic target for SLE.
  • To elucidate how C1q deficiency may lead to defective self-tolerance.

Main Methods:

  • Review of existing literature on C1q, C1qRs, monocyte-DC differentiation, and SLE.
  • Analysis of the proposed mechanisms by which C1q influences immune cell function.
  • Discussion of the implications of C1q deficiency in autoimmune disease development.

Main Results:

  • While C1q aids in apoptotic debris clearance, its absence does not fully abrogate this process due to redundant mechanisms.
  • C1q actively suppresses monocyte differentiation into DCs, preventing premature immune activation.
  • C1q deficiency is hypothesized to dysregulate monocyte-to-DC differentiation, leading to impaired self-tolerance and potentially SLE.

Conclusions:

  • The second hypothesis, focusing on C1q's role in monocyte-DC regulation, offers a compelling explanation for C1q deficiency in SLE.
  • C1q receptors (cC1qR and gC1qR) on monocytes and DCs suggest C1q signaling pathways are critical for immune regulation.
  • Targeting the gC1qR/C1q axis presents a promising therapeutic avenue for managing SLE.